Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1638-1646

  Siegelin, Markus D ^a   Plescia, Janet ^a   Raskett, Christopher M ^a   Gilbert, Candace A ^a   Ross, Alonzo H ^a   Altieri, Dario C ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN TRAP 1; SHEPHERDIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER GROWTH; CANCER INHIBITION; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; FETUS; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOPHILINS; FEMALE; GLIOBLASTOMA; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; MICE; MIDDLE AGED; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; PEPTIDE FRAGMENTS; SUBCELLULAR FRACTIONS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953468176     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0097     Document Type: Article

References (34)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99. (Pubitemid 39070849)
2. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
3. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-37.
4. Stein WD, Bates SE, Fojo T. Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr Drug Targets 2004;5:333-46.
5. Purow B, Schiff D. Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol 2009;5:419-26.
6. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
7. Brown PD, Krishnan S, Sarkaria JN, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 2008;26:5603-9.
8. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 2009;96:219-30.
9. Thiessen B, Stewart C, Tsao M, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 2009. EPub ahead of print June 5, 2009, PMID:19499221.
10. Lino M, Merlo A. Translating biology into clinic: the case of glioblastoma. Curr Opin Cell Biol 2009;21:311-6.
11. Butcher EC. Can cell systems biology rescue drug discovery? Nat Rev Drug Discov 2005;4:461-7.
12. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7. (Pubitemid 37443877)
13. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
14. Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J. Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel 2006;9:483-95.
15. Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 2002;296: 2232-5.
16. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002;295:1852-8. (Pubitemid 34214115)
17. Frey S, Leskovar A, Reinstein J, Buchner J. The ATPase cycle of the endoplasmic chaperone Grp94. J Biol Chem 2007;282:35612-20. (Pubitemid 350277115)
18. Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007;131:257-70. (Pubitemid 47576138)
19. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626-9.
20. Kang BH, Plescia J, Song HY, et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest 2009;119:454-64.
21. Plescia J, Salz W, Xia F, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005;7:457-68. (Pubitemid 40719129)
22. Siegelin MD, Habel A, Gaiser T. 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis. Neurobiol Dis 2009;33: 243-9.
23. Gaiser T, Becker MR, Meyer J, Habel A, Siegelin MD. p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas. Neuro-chem Int 2009;54:458-63.
24. Jiang H, White EJ, Conrad C, Gomez-Manzano C, Fueyo J. Autophagy pathways in glioblastoma. Methods Enzymol 2009;453:273-86.
25. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 2006;8:343-75.
26. Samudio I, Kurinna S, Ruvolo P, et al. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28- oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol Cancer Ther 2008;7:1130-9.
27. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004;11:448-57. (Pubitemid 38489422)
28. Kim W-Y, Oh SH, Woo J-K, Hong WK, Lee H-Y. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor- 1{alpha}. Cancer Res 2009;69:1624-32.
29. Okawa Y, Hideshima T, Steed P, et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009; 113:846-55.
30. Beere HM. "The stress of dying": the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004;117:2641-51.
31. Dungey FA, Caldecott KW, Chalmers AJ. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther 2009;8:2243-54.
32. Gaspar N, Sharp SY, Pacey S, et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 2009;69:1966-75.
33. Tagscherer KE, Fassl A, Campos B, et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008;27:6646-56.
34. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425:407-10. (Pubitemid 37187270)